Literature DB >> 16505204

Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling.

Peter Pokreisz1, Ingrid Fleming, Ladislau Kiss, Eduardo Barbosa-Sicard, Beate Fisslthaler, John R Falck, Bruce D Hammock, In-Hae Kim, Zsolt Szelid, Pieter Vermeersch, Hilde Gillijns, Marijke Pellens, Friedrich Grimminger, Anton-Jan van Zonneveld, Desire Collen, Rudi Busse, Stefan Janssens.   

Abstract

We assessed pulmonary cytochrome P450 (CYP) epoxygenase expression and activity during hypoxia and explored the effects of modulating epoxygenase activity on pulmonary hypertension. The acute hypoxic vasoconstrictor response was studied in Swiss Webster mice, who express CYP2C29 in their lungs. Animals were pretreated with vehicle, the epoxygenase inhibitor (N-methylsulfonyl-6-[2-propargyloxyphenyl] hexanamide) or an inhibitor of the soluble epoxide hydrolase. Whereas the epoxygenase inhibitor attenuated hypoxic pulmonary constriction (by 52%), the soluble epoxide hydrolase inhibitor enhanced the response (by 39%), indicating that CYP epoxygenase-derived epoxyeicosatrienoic acids elicit pulmonary vasoconstriction. Aerosol gene transfer of recombinant adenovirus containing the human CYP2C9 significantly elevated mean pulmonary artery pressure and total pulmonary resistance indices, both of which were sensitive to the inhibitor sulfaphenazole. The prolonged exposure of mice to hypoxia increased CYP2C29 expression, and transcript levels increased 5-fold after exposure to normobaric hypoxia (FIO2 0.07) for 2 hours. This was followed by a 2-fold increase in protein expression and by a significant increase in epoxyeicosatrienoic acid production after 24 hours. Chronic hypoxia (7 days) elicited pulmonary hypertension and pulmonary vascular remodeling, effects that were significantly attenuated in animals continually treated with N-methylsulfonyl-6-[2-propargyloxyphenyl] hexanamide (-46% and -55%, respectively). Our results indicate that endogenously generated epoxygenase products are associated with hypoxic pulmonary hypertension in mice and that selective epoxygenase inhibition significantly reduces acute hypoxic pulmonary vasoconstriction and chronic hypoxia-induced pulmonary vascular remodeling. These observations indicate potential novel targets for the treatment of pulmonary hypertension and highlight a pivotal role for CYP epoxygenases in pulmonary responses to hypoxia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505204      PMCID: PMC1993904          DOI: 10.1161/01.HYP.0000208299.62535.58

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  36 in total

Review 1.  Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD.

Authors:  J Hukkanen; O Pelkonen; H Raunio
Journal:  Eur Respir J Suppl       Date:  2001-09

2.  Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia.

Authors:  Scott Earley; Andrzej Pastuszyn; Benjimen R Walker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-03-06       Impact factor: 4.733

3.  Selective inhibition of arachidonic acid epoxidation in vivo.

Authors:  E Brand-Schieber; J F Falck; M Schwartzman
Journal:  J Physiol Pharmacol       Date:  2000-12       Impact factor: 3.011

4.  Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1.

Authors:  Michael Potente; U Ruth Michaelis; Beate Fisslthaler; Rudi Busse; Ingrid Fleming
Journal:  J Biol Chem       Date:  2002-02-26       Impact factor: 5.157

5.  Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids.

Authors:  Jianxin Sun; XinXin Sui; J Alyce Bradbury; Darryl C Zeldin; Michael S Conte; James K Liao
Journal:  Circ Res       Date:  2002-05-17       Impact factor: 17.367

6.  Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction.

Authors:  Fumito Ichinose; Roman Ullrich; Adam Sapirstein; Rosemary C Jones; Joseph V Bonventre; Charles N Serhan; Kenneth D Bloch; Warren M Zapol
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 7.  Cytochrome p450 and vascular homeostasis.

Authors:  I Fleming
Journal:  Circ Res       Date:  2001-10-26       Impact factor: 17.367

Review 8.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

9.  Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.

Authors:  Stephan Fichtlscherer; Stefanie Dimmeler; Susanne Breuer; Rudi Busse; Andreas M Zeiher; Ingrid Fleming
Journal:  Circulation       Date:  2003-12-08       Impact factor: 29.690

Review 10.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.

Authors:  Arthur A Spector; Xiang Fang; Gary D Snyder; Neal L Weintraub
Journal:  Prog Lipid Res       Date:  2004-01       Impact factor: 16.195

View more
  48 in total

Review 1.  Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease.

Authors:  Ning Li; Jun-Yan Liu; Hong Qiu; Todd R Harris; Padmini Sirish; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Congest Heart Fail       Date:  2011-01-27

Review 2.  Transient receptor potential channels in the vasculature.

Authors:  Scott Earley; Joseph E Brayden
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 3.  Soluble epoxide hydrolase inhibitors and heart failure.

Authors:  Hong Qiu; Ning Li; Jun-Yan Liu; Todd R Harris; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Cardiovasc Ther       Date:  2011-04       Impact factor: 3.023

4.  Hypoxic pulmonary vasoconstriction requires connexin 40-mediated endothelial signal conduction.

Authors:  Liming Wang; Jun Yin; Hannah T Nickles; Hannes Ranke; Arata Tabuchi; Julia Hoffmann; Christoph Tabeling; Eduardo Barbosa-Sicard; Marc Chanson; Brenda R Kwak; Hee-Sup Shin; Songwei Wu; Brant E Isakson; Martin Witzenrath; Cor de Wit; Ingrid Fleming; Hermann Kuppe; Wolfgang M Kuebler
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

Review 5.  The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.

Authors:  Sean D Kodani; Bruce D Hammock
Journal:  Drug Metab Dispos       Date:  2015-03-11       Impact factor: 3.922

6.  Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.

Authors:  Kimberly L Fife; Yingmei Liu; Kara R Schmelzer; Hsing-Ju Tsai; In-Hae Kim; Christophe Morisseau; Bruce D Hammock; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-09-24       Impact factor: 4.030

7.  Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.

Authors:  Robert B Cotton; Lisa P Shah; Stanley D Poole; Noah J Ehinger; Naoko Brown; Elaine L Shelton; James C Slaughter; H Scott Baldwin; Bibhash C Paria; Jeff Reese
Journal:  J Mol Cell Cardiol       Date:  2013-02-27       Impact factor: 5.000

8.  Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo.

Authors:  Ding Ai; Yi Fu; Deliang Guo; Hiromasa Tanaka; Nanping Wang; Chaoshu Tang; Bruce D Hammock; John Y-J Shyy; Yi Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-10       Impact factor: 11.205

Review 9.  Roles of the epoxygenase CYP2J2 in the endothelium.

Authors:  Ara Askari; Scott J Thomson; Matthew L Edin; Darryl C Zeldin; David Bishop-Bailey
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-03-06       Impact factor: 3.072

10.  Inhibition of the soluble epoxide hydrolase by tyrosine nitration.

Authors:  Eduardo Barbosa-Sicard; Timo Frömel; Benjamin Keserü; Ralf P Brandes; Christophe Morisseau; Bruce D Hammock; Thomas Braun; Marcus Krüger; Ingrid Fleming
Journal:  J Biol Chem       Date:  2009-08-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.